Please assess the completion status of the following clinical trial:

Trial Title: Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is prescribed.~* At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal status~* Having expressed their written free and informed consent~Exclusion Criteria:~* Hypersensitivity to any of the following components : tocilizumab, saccharose, polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate~* Severe or active infections~* Systemic Pathology affecting the immune system including Sjögren's syndrome~* Surgery in the previous month~* HIV positive~* Alcoholic~* Toxicoman~* Antibiotic treatment in the last 2 months~* Legally protected patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient with parodontitis (Type: OTHER): Patient with rheumatoid arthritis and pparodontitis.
- Patient without parodontitis (Type: OTHER): Patient with rheumatoid arthritis but periodontally healthy

Based on this trial design, predict the completion outcome and termination type (if applicable).